A detailed history of Birchview Capital, LP transactions in Uni Qure N.V. stock. As of the latest transaction made, Birchview Capital, LP holds 20,000 shares of QURE stock, worth $114,000. This represents 0.09% of its overall portfolio holdings.

Number of Shares
20,000
Holding current value
$114,000
% of portfolio
0.09%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.78 - $10.12 $75,600 - $202,399
20,000 New
20,000 $98,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $266M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.